ONCY

Oncolytics Biotech Inc

• Dow Jones·08/19 12:48

  Oncolytics Biotech Is Maintained at Buy by HC Wainwright & Co.

• Dow Jones·08/19 12:48

  Oncolytics Biotech Price Target Cut to $5.00/Share From $10.00 by HC Wainwright & Co.

• Benzinga·08/19 12:37

  HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5

• TipRanks·08/19 10:05

  Oncolytics price target lowered to $5 from $10 at H.C. Wainwright

• TipRanks·08/18 13:33

  Oncolytics Biotech gains FDA alignment on REO 033 trial

• TipRanks·08/18 13:16

  Oncolytics aligns with FDA on path for REO 033 expansion study

• Benzinga·08/18 13:03

  Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design

• TipRanks·07/24 20:56

  Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance

• NASDAQ·07/21 07:03

  Oncolytics' Pelareorep Gets Fast Track Designation In Second-Line And Later Anal Cancer; Stock Down

• TipRanks·07/20 13:28

  Oncolytics Biotech gains FDA Fast Track for pelareorep

• TipRanks·07/20 13:06

  Oncolytics announces FDA Fast Track designation for pelareorep

• Benzinga·07/20 13:01

  Oncolytics Biotech Receives FDA's Fast Track Designation To Pelareorep In Combination With A Checkpoint Inhibitor Treat Squamous Cell Carcinoma Of Anal Canal

• TipRanks·07/13 20:40

  Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Olema Pharmaceuticals (OLMA)

• TipRanks·07/13 17:25

  Oncolytics Biotech advances REO 033 colorectal cancer program

• TipRanks·07/13 16:40

  Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)